Evaluation of results 1 year following short-term use of ranibizumab for vitreous hemorrhage due to proliferative diabetic retinopathy

JAMA Ophthalmology

Volumn 132, Issue 7, 2014, Pages 889-890

  Bhavsar, Abdhish R ^a   Torres, Karisse ^b   Glassman, Adam R ^b   Jampol, Lee M ^c   Kinyoun, James L ^d  

^a Retina Center of Minnesota   (United States)

^b JAEB CENTER FOR HEALTH RESEARCH   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

ADVERSE OUTCOME; CLINICAL EXAMINATION; DIABETIC RETINOPATHY; DRUG USE; FOLLOW UP; HUMAN; LETTER; PRIORITY JOURNAL; RETINA DETACHMENT; VISUAL ACUITY; VISUAL ACUITY CHART; VITRECTOMY; VITREOUS HEMORRHAGE;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETIC RETINOPATHY; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; LASER COAGULATION; MALE; MIDDLE AGED; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITRECTOMY; VITREOUS HEMORRHAGE;

EID: 84904162871     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2014.287     Document Type: Letter

References (2)

1. Kempen JH, O'Colmain BJ, Leske MC, et al; Eye Diseases Prevalence Research Group. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol. 2004;122(4):552-563. (Pubitemid 38456292)
2. Diabetic Retinopathy Clinical Research Network*. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. JAMA Ophthalmol. 2013;131(3):283-293.